Neuren Pharmaceuticals Limited
Status: Publicly traded
Direct answer
Neuren Pharmaceuticals Limited is publicly traded on ASX under the ticker NEU.AX.
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the...
Can you invest in Neuren Pharmaceuticals Limited?
Yes. Neuren Pharmaceuticals Limited trades publicly on ASX as NEU.AX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Neuren Pharmaceuticals Limited
Detailed equity research is provided by MarketSnap.